Literature DB >> 19453282

The do's and don'ts of p53 isoforms.

Reiner U Jänicke1, Vilma Graupner, Wilfried Budach, Frank Essmann.   

Abstract

Upon DNA damage and other stresses, the transcription factor p53 elicits numerous responses including DNA repair, cell cycle arrest and apoptosis, properties that make p53 the prototype tumor suppressor. In addition, p53 also transactivates genes whose products act in an anti-apoptotic manner providing strong evidence that p53 exhibits both tumor suppressive and tumorigenic functions. Although several events were postulated to contribute to the p53-mediated decision process, the precise mechanism(s) that governs p53 activities is still elusive. Recently, it was found that the p53 gene allows expression of at least nine different isoforms that arise from multiple splicing events and the usage of alternative promoters. Several of these isoforms were shown to critically interfere with the function of the full-length p53 mainly by acting in a dominant-negative manner. However, an isoform-dependent selective activation of p53 target genes was also observed. Furthermore, certain p53 isoforms are aberrantly expressed in various tumors strongly implying their involvement in tumorigenic events. Thus, p53 isoforms may represent crucial determinants in p53-mediated decision processes whose precise functions (their do's and don'ts) are only beginning to emerge.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19453282     DOI: 10.1515/BC.2009.093

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  14 in total

1.  Discovery of TP53 splice variants in two novel papillary urothelial cancer cell lines.

Authors:  Annemarie Koch; Jiri Hatina; Harald Rieder; Hans-Helge Seifert; Wolfgang Huckenbeck; Frank Jankowiak; Andrea R Florl; Robert Stoehr; Wolfgang A Schulz
Journal:  Cell Oncol (Dordr)       Date:  2012-06-06       Impact factor: 6.730

2.  Extensive post-translational modification of active and inactivated forms of endogenous p53.

Authors:  Caroline J DeHart; Jasdave S Chahal; S J Flint; David H Perlman
Journal:  Mol Cell Proteomics       Date:  2013-09-20       Impact factor: 5.911

Review 3.  Metabolic reprogramming and dysregulated metabolism: cause, consequence and/or enabler of environmental carcinogenesis?

Authors:  R Brooks Robey; Judith Weisz; Nancy B Kuemmerle; Anna C Salzberg; Arthur Berg; Dustin G Brown; Laura Kubik; Roberta Palorini; Fahd Al-Mulla; Rabeah Al-Temaimi; Annamaria Colacci; Chiara Mondello; Jayadev Raju; Jordan Woodrick; A Ivana Scovassi; Neetu Singh; Monica Vaccari; Rabindra Roy; Stefano Forte; Lorenzo Memeo; Hosni K Salem; Amedeo Amedei; Roslida A Hamid; Graeme P Williams; Leroy Lowe; Joel Meyer; Francis L Martin; William H Bisson; Ferdinando Chiaradonna; Elizabeth P Ryan
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

Review 4.  Translational approaches targeting the p53 pathway for anti-cancer therapy.

Authors:  Frank Essmann; Klaus Schulze-Osthoff
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

5.  Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation.

Authors:  Jennifer J Jordan; Alberto Inga; Kathleen Conway; Sharon Edmiston; Lisa A Carey; Lin Wu; Michael A Resnick
Journal:  Mol Cancer Res       Date:  2010-04-20       Impact factor: 5.852

6.  Given dimensions of neoplastic events as aberrantly operative alternative splicing.

Authors:  Lawrence M Agius
Journal:  Patholog Res Int       Date:  2009-10-12

7.  Lysines in the tetramerization domain of p53 selectively modulate G1 arrest.

Authors:  Rachel Beckerman; Kathryn Yoh; Melissa Mattia-Sansobrino; Andrew Zupnick; Oleg Laptenko; Orit Karni-Schmidt; Jinwoo Ahn; In-Ja Byeon; Susan Keezer; Carol Prives
Journal:  Cell Cycle       Date:  2016-05-21       Impact factor: 4.534

8.  Identification of tumor-associated cassette exons in human cancer through EST-based computational prediction and experimental validation.

Authors:  Alessio Valletti; Anna Anselmo; Marina Mangiulli; Ilenia Boria; Flavio Mignone; Giuseppe Merla; Vincenzo D'Angelo; Apollonia Tullo; Elisabetta Sbisà; Anna Maria D'Erchia; Graziano Pesole
Journal:  Mol Cancer       Date:  2010-09-02       Impact factor: 27.401

9.  Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer.

Authors:  G Hofstetter; A Berger; E Schuster; A Wolf; G Hager; I Vergote; I Cadron; J Sehouli; E I Braicu; S Mahner; P Speiser; C Marth; A G Zeimet; H Ulmer; R Zeillinger; N Concin
Journal:  Br J Cancer       Date:  2011-10-18       Impact factor: 7.640

10.  miR-30e controls DNA damage-induced stress responses by modulating expression of the CDK inhibitor p21WAF1/CIP1 and caspase-3.

Authors:  Dennis Sohn; Dominik Peters; Roland P Piekorz; Wilfried Budach; Reiner U Jänicke
Journal:  Oncotarget       Date:  2016-03-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.